GCCL and KoNECT Sign MOU for Mutual Cooperation

Strengthening Quality Capabilities in Clinical Trial Sample Analysis
and Sharing of Technologies

Global clinical trial sample analysis institution GCCL announced on July 30 that it had signed a memorandum of understanding (MOU) for mutual cooperation in clinical research with the Korea National Enterprise for Clinical Trials (KoNECT) on July 29.

Park Inseok, Chairman of the National Clinical Trial Support Foundation (left), and Cho Gwan-gu, CEO of GCGL (right), signed a business agreement on the 29th at GCGL in Yongin, Gyeonggi Province, and took a commemorative photo. GCGL

The signing ceremony, held at the GCCL facility in Yongin, Gyeonggi Province, was attended by Park Inseok, Chairman of KoNECT, and Cho Kwangoo, CEO of GCCL, along with officials from both organizations. Through this agreement, the two institutions aim to strengthen the quality capabilities of domestic clinical trial sample analysis and to establish a foundation for policy and technological cooperation to enhance global competitiveness.

The main contents of the MOU include: establishing an institutional foundation and policy cooperation to strengthen the quality capabilities of clinical trial sample analysis; sharing the latest domestic and international medical and clinical information related to sample analysis technologies and clinical trial issues recognized by each institution; jointly operating educational programs and exchanging technical and academic information; cooperating in domestic and international promotion through sharing networks and infrastructure; and other areas of mutual interest as necessary.

The two organizations are expected to contribute to the qualitative advancement of the domestic clinical trial environment and to strengthening new drug development capabilities by establishing an institutional foundation for expanding the domestic clinical trial sample analysis market and improving analysis quality, as well as by pursuing practical joint projects.

Park Inseok, Chairman of KoNECT, stated, "This MOU is an important milestone in establishing a practical cooperation model that can connect policy with the field. Going forward, based on our role as the National Clinical Trial Support Center, we will continue to work closely with the industry and make ongoing efforts to improve the quality of clinical trials and enhance the global competitiveness of the pharmaceutical and bio industries."

Cho Kwangoo, CEO of GCCL, said, "It is very meaningful to be able to raise the quality standards of clinical trial sample analysis and support the global expansion of the domestic pharmaceutical and bio industries together with KoNECT. Based on our globally recognized analytical capabilities, we will strengthen our strategic cooperation with public institutions and provide differentiated clinical sample analysis services to the global market."

Meanwhile, GCCL is a clinical trial sample analysis institution that has obtained certification in all areas of Good Clinical Laboratory Practice (GCLP) from the Ministry of Food and Drug Safety. It provides customized clinical analysis services that meet global standards for all phases of clinical trials, from Phase 1 to Phase 4.